Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06873516 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
A Phase 2 study of Chronic Spontaneous Urticaria, sponsored by Evommune.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT06873516: Recruiting Phase 2 study of Chronic Spontaneous Urticaria, sponsored by Evommune.
NCT06873516 is a Phase 2 study of Chronic Spontaneous Urticaria that is actively recruiting participants, run by Evommune. The registered enrollment target is 160 participants, below the 1,418-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06873516, a Phase 2 study of Chronic Spontaneous Urticaria, is actively recruiting participants, sponsored by Evommune.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
Conditions Studied
Interventions
- DRUG EVO756
- DRUG Placebo control
Study Locations (20)
California
- Center for Dermatology Clinical Research - Fremont
- Antelope Valley Clinical Trials - Lancaster
- Northridge Clinical Trials - Northridge
- NorthBay Clinical Research - Santa Rosa
- Integrated Research of Inland - Upland
- FOMAT Medical Research - Ventura
Louisiana
- Delricht Research Louisiana - Baton Rouge
- Velocity Clinical Research, Lafayette - Lafayette
- Delricht Research - New Orleans
Alabama
- Cahaba Dermatology Skin Health Center - Birmingham
- Velocity Clinical Research, Mobile - Mobile
Florida
- AMR Fort Myers - Fort Myers
- Advanced Clinical Research Institute - Tampa
Kentucky
- Bluegrass Allergy Care - Lexington
- Delricht Research Louisville - Louisville
Illinois
- Sneeze, Wheeze & Itch Associates LLC - Normal
Indiana
- The Indiana Clinical Trials Center - Plainfield
Iowa
- The Iowa Clinic - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What NCT06873516 shows while recruiting
NCT06873516 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,418-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Chronic Spontaneous Urticaria appearing as the primary indexed condition, and to 2 interventions - of which EVO756 is the first listed.
NCT06873516 names 20 study sites across 10 states, led by California, Louisiana, Alabama.
Frequently Asked Questions
What is clinical trial NCT06873516 about?
NCT06873516 is a clinical study titled "Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)". This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
What is the current status of trial NCT06873516?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-03-20. Estimated completion is 2026-05.
What conditions does trial NCT06873516 study?
This clinical trial studies the following conditions: Chronic Spontaneous Urticaria.
What interventions are being tested in trial NCT06873516?
The interventions under investigation include: EVO756 (DRUG), Placebo control (DRUG).
Who is sponsoring clinical trial NCT06873516?
This trial is sponsored by Evommune, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06873516 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Spontaneous Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06873516's enrollment target sits among peer trials
160 13th of 18 higher than 6 of 18 other Chronic Spontaneous Urticaria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Spontaneous Urticaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
RECRUITING · Phase 2
-
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
RECRUITING · Phase 2
-
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU
COMPLETED · Phase 2
-
Remibrutinib in Real-world Clinical Practice - a US Sub-study
RECRUITING
-
Remibrutinib in Real-world Clinical Practice
RECRUITING
-
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI